New imaging technique for pancreatic cancer treatment response
Official title: Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
Funded at Washington University · NIH-10927190 · Data updated 2026-11-12
This study is testing a new imaging method to help doctors see pancreatic cancer better and understand how well different treatments might work for patients, so they can tailor the best care for each person.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | January 1, 2019 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $252,589 |
| NIH project number | 5R01CA235672-06 |
| Project ID | NIH-10927190 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma (PDAC) who are undergoing treatment.
✕Less likely to help
Patients with other types of cancer or those who are not diagnosed with PDAC may not benefit from this research.
What this research studies
This research focuses on developing a novel imaging technique using CCR2 PET to better visualize pancreatic cancer and predict how well patients will respond to standard therapies and new CCR2-targeted treatments. By understanding the tumor microenvironment and the role of specific immune cells, the research aims to enhance treatment effectiveness. Patients will be monitored through advanced imaging to assess the presence of CCR2, which is linked to tumor growth and treatment resistance. The goal is to create a diagnostic tool that can guide personalized treatment strategies for pancreatic cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment plans for patients with pancreatic cancer, improving their chances of recovery.
How similar studies have gone: Previous research has shown promising results in targeting the CCR2 pathway in preclinical models, indicating potential for success in clinical applications.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Dehdashti, Farrokh — Washington University
- Study coordinator: Dehdashti, Farrokh
Related research
Other NIH-funded projects on the same topics.
-
PSCA-targeted antibody for imaging and treating pancreatic cancer
A specially engineered antibody is used to find and deliver targeted radiation to pancreatic tumors that have high PSCA levels.
-
Targeted therapy using engineered antibodies for pancreatic cancer
This study is testing a new type of treatment for advanced pancreatic cancer that uses specially designed antibodies to target a specific protein found in many pancreatic tumors, aiming to make the treatment more effective while protecting healthy organs from radiation.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.